Aktieanalys

XVIVO Perfusion: Q2, XVIVO delivers improved growth with a solid outlook - Redeye

Redeye Publicerad: 13 Jul 2021 14:26

The Thoracic business delivers CER organic growth of 82% with improved gross margins with significant US support. Both the Thoracic and the Abdominal business (underlying organic Q2 growth of 126%) is likely to improve in Europe, where some countries suffer from more extensive lockdowns. In 2021, we can expect more support from UK sales and a US launch of Kidney Assist Transport. We expect a positive reaction on the back of Q2 and improved structural support ahead.

https://www.redeye.se/research/816867/xvivo-perfusion-q2-xvivo-delivers-improved-growth-with-a-solid-outlook?utm_source=finwire&utm_medium=RSS

Nyheter om Xvivo Perfusion

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!